Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation. The presentation will detail an additional risk threshold previously established within the MammaPrint Low Risk category, identifying patients with an Ultra Low Risk of distant recurrence, essentially meaning the patient’s tumor is very unlikely to recur or metastasize over at least 20 years of follow-up, according to prior studies. This information could be helpful in further tailoring adjuvant treatment for patients with early stage breast cancer.
In the oral presentation, titled “Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial,” Josephine Lopes Cardozo, MD, first author of the abstract, PhD Candidate at the Netherlands Cancer Institute and fellow at the EORTC, will outline that in the MINDACT study, patients with an UltraLow Risk signature have an excellent prognosis, with 8-year breast cancer specific survival above 99% regardless of clinical risk status, and an 8-year distant metastasis free interval of 97%. The presentation, part of ASCO 2021’s Breast Cancer track, can be accessed here.
“The Ultra Low threshold identifies patients who may be candidates for further de-escalation of treatment,” said Dr. Lopes Cardozo. “To give the patient’s care team this kind of prognostic insight at the time of diagnosis will hopefully allow for many patients to avoid over treatment and further reduce the risk of side effects while maintaining excellent survival.”
The MINDACT trial, an independent, phase III, prospective, randomized clinical trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC), was conducted with the primary goal of determining whether Agendia’s 70-gene MammaPrint® test could be used to de-escalate clinically high risk patients with early stage breast cancer from chemotherapy treatment. The study enrolled nearly 7,000 patients with newly-diagnosed breast cancer, and at median long-term follow-up of 8.7 years, 46% of clinically high risk patients with a MammaPrint Low Risk result could forgo chemotherapy without negatively affecting their outcomes. These data were recently published in The Lancet Oncology .
The current study to be presented at ASCO focuses on the clinical characteristics and outcomes of the 1,000 women with a MammaPrint Ultra Low risk status enrolled in MINDACT. Consistent with three prior studies presented since 2017, these data show a nearly 100% breast cancer specific survival at 8 years, with 5 years of anti-estrogen therapy, and excellent outcomes (97.8% DMFI) for the 157 Ultra Low Risk women who received no systemic therapy.
“The confirmation of the clinical importance and excellent prognosis of the MammaPrint Ultra Low Risk category provides further support for the inclusion of this information in the management of endocrine therapy, particularly for those women experiencing severe side effects, and struggling to remain on their prescribed treatment,” said William Audeh, MD, Chief Medical Officer at Agendia. “We are extremely proud to have contributed to the EORTC’s MINDACT study, which has influenced the clinical treatment of patients and will inspire ongoing translational research that will contribute to the library of data we need to personalize the treatment of breast cancer.”
Beyond answering the traditional adjuvant chemotherapy question, the MINDACT study continues to produce a wealth of insights with immediately meaningful clinical implications and access to an unprecedented full genome dataset for further research, resulting in widespread health system cost savings.
At ASCO 2021, Agendia also presented a larger suite of data from the company’s groundbreaking FLEX registry, a large-scale, prospective, observational breast cancer study using whole transcriptome sequencing, recruiting patients from various ethnicities, ages and genders representative of the total breast cancer population as part of an ongoing effort to increase representation of diverse populations and data in clinical trials.
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Westwicke/ICR Healthcare PR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Go for Goal at Golden Euro Casino16.6.2021 14:01:00 EEST | Press release
The UEFA European Football Championship kicked off over the weekend and already it looks set to be one of the most thrilling tournaments in recent history. But to make the contest even more exciting, Golden Euro is running a special promotion. Players at the popular online casino are being given the chance to go for goal with 21 Free Spins each day on Realtime Gaming’s Football Fortunes. The promo runs until 11 July and you can win a up to €25 every day from the Free Spins, which can be activated with the code EURO21. Football Fortunes has an incredible line-up of bonus features, including Wilds, Multipliers, Free Spins, three different game modes – Rhino, Fortune and Penalty Kick – and not one but two progressive jackpots that seed at €1,600 and €970. The Rhino mode is triggered when three, four or five Mascot Scatter symbols land anywhere on the reels, triggering 8, 10-25 or 50-100 Free Spins respectively. All wins are tripled while Rhino mode is active, and Ball Wilds can appear gro
Enevate's Next Generation Battery Technology Provides Lower Carbon Footprint During Electric Vehicle (EV) Manufacturing16.6.2021 14:00:00 EEST | Press release
Enevate, a pioneering battery innovation company featuring extreme fast charge and high energy density battery technologies for electric vehicles (EVs) and other markets, delivers up to 27 percent reduction of carbon dioxide (CO2) emissions for manufacturing of EV batteries with Enevate's XFC-EnergyTM technology compared to today's conventional lithium-ion EV batteries (21 percent for NCA and 27 percent for NMC cells [kg CO2 eq. cradle-to-gate, per 1 KWh cell capacity]).1 These accomplishments have the potential to lower an EV's carbon footprint at the start of life, which is significant because battery manufacturing is the highest contributor of CO2 emissions for the manufacturing of an EV. Enevate utilizes a higher energy density material and an innovative, ultra-thin multi-layer design in its large format EV cells that meet the demanding EV specifications. Enevate's battery technology strives to provide EV and battery companies with a process for taking measurable, cost-effective st
Distrupol Acquires Lautrup Chemicals16.6.2021 13:36:00 EEST | Press release
Distrupol, a leading European distributor of thermoplastics and elastomers to the polymer processing industry and an affiliate of GPD Companies, Inc. (“GPD”), today announced that it has acquired Lautrup Chemicals A/S (“Lautrup Chemicals” or the “Company”). Terms of the transaction were not disclosed. Founded in 1982 by Chief Executive Officer and President Hans Lautrup, Lautrup Chemicals is the leading distributor of polymers in Scandinavia. The Company provides a broad portfolio of high-quality polymer products from premier suppliers to a diverse client base across the Nordic region as well as Eastern and Southern Europe. Headquartered in Copenhagen, Denmark, Lautrup Chemicals has a highly qualified team and network of strategically located distribution warehouses throughout the continent, designed to provide safe and efficient product delivery. “Over nearly 40 years, Lautrup Chemicals has established an incredible reputation for providing exceptional service, an expansive product po
The EUROGLIDER Autonomous Electric Glider Project Takes Off16.6.2021 12:22:00 EEST | Press release
The result of an innovative partnership involving the European Association for the Development of Gliding (AEDEVV), Dassault Aviation and the engineering schools of the ISAE Group, the EUROGLIDER project aims to develop an electrically powered two-seater glider for training, release and practice. At the crossroads of several technological challenges, the project is currently in the experimental test phase and will shortly begin preparations for its industrial phase. The ambition of this glider is to be able to carry out complete instructional flights autonomously without having to wait for favorable aerological conditions and while preserving the environment. The EUROGLIDER project attempts to satisfy the requests of the European gliding training centers. Because of a long waiting period, nearly 2/3 of the new registrants give up before their first "solo" flight. Thanks to its electric propulsion, the EUROGLIDER will be able to link several training flights of more than 40 minutes in a
Guidewire Wins Three XCelent Awards for Claims in EMEA16.6.2021 12:00:00 EEST | Press release
Guidewire Software, Inc. (NYSE: GWRE), the platform general insurers trust to engage, innovate, and grow efficiently, today announced that ClaimCenter has been named a winner of three awards in Celent’s P&C Claims Systems Vendors in EMEA, 2021 Edition. ClaimCenter was recognised as the top solution amongst the 20 core claims solutions evaluated, in the Breadth of Functionality, Customer Base, and Depth of Customer Service categories. An extract from the report can be read here. "The key story with the release of Aspen is the step change in how InsuranceSuite will be delivered to customers. In addition to the cloud investment and the push towards Guidewire Cloud services, there is the increased cadence of releases - perhaps the greatest change to ClaimCenter in its lifetime," said Craig Beattie, senior analyst, Celent, and report author. "Overall, ClaimCenter remains the strongest performing claims system in the European market." "We are honoured to receive this recognition from Celent,
Procuritas Creates New IT Services Platform in Finland16.6.2021 11:00:00 EEST | Press release
Procuritas Capital Investors VI (“Procuritas”) today announces the launch of Frendy, a new IT services platform based in Finland. The new company has been created through the acquisition of twelve IT services businesses across the country. After the transaction, Procuritas will become the majority shareholder, with the current entrepreneurial teams continuing in the day-to-day management of their local businesses with significant minority ownership of the wider company. Frendy will deliver IT services for SME companies in Finland, a target market of more than €1 billion per annum. At inception, the company will have 160 employees in 16 locations across Finland and will be headquartered in Helsinki, with revenues in excess of €33 million. Jussi Holopainen, Investment Manager at Procuritas, commented, “We are delighted to have completed the formation of Frendy. It is a really exciting opportunity for Procuritas to create a new company in this sizeable fragmented market currently serving
BehavioSec Granted U.S. Patents for Mobile Authentication and Social Engineering Detection16.6.2021 10:00:00 EEST | Press release
BehavioSec, the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced the successful grant of two additional U.S. patents for its innovative method of verifying user identity and detecting fraud. Since its 2008 founding, BehavioSec has successfully been granted 24 U.S. patents, demonstrating the company’s continual commitment to the innovation and development of behavioral biometrics technology. With this new addition to their patent portfolio, BehavioSec technology can better protect digital identities and consumers on mobile devices from increasingly sophisticated, social engineering attacks – helping stop fraud before the damage is done. Today, BehavioSec already protects over 180 million people and 20 billion annual transactions across the globe. But as mobile devices continue to increase as a means of conducting financial transactions and accessing account information, consumers and institutions are often trading security a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom